



HHS Public Access

Author manuscript

J Infect Dis. Author manuscript; available in PMC 2020 July 06.

Published in final edited form as:

J Infect Dis. 2018 January 04; 217(2): 245–256. doi:10.1093/infdis/jix571.

Severe Influenza Is Characterized by Prolonged Immune Activation: Results From the SHIVERS Cohort Study

Sook-San Wong¹, Christine M. Oshansky^{2,a}, Xi-Zhi J. Guo^{2,3}, Jacqui Ralston⁵, Timothy Wood⁵, Ruth Seeds⁵, Claire Newbern⁵, Ben Waite⁵, Gary Reynolds⁶, Marc-Alain Widdowson⁴, Q. Sue Huang⁵, Richard J. Webby^{1,b}, Paul G. Thomas^{2,3,b}, SHIVERS Investigation Team^c

¹Department of Infectious Diseases, University of Tennessee Health Science Center, Memphis

²Department of Immunology, St. Jude Children's Research Hospital, University of Tennessee Health Science Center, Memphis ³Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis ⁴Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia ⁵Institute for Environmental Science and Research, National Centre for Biosecurity and Infectious Disease—Wallaceville, Upper Hutt, University of Auckland, New Zealand ⁶Immunisation Advisory Service, Department of Population Health, University of Auckland, New Zealand

Abstract

Background.—The immunologic factors underlying severe influenza are poorly understood. To address this, we compared the immune responses of influenza-confirmed hospitalized individuals with severe acute respiratory illness (SARI) to those of nonhospitalized individuals with influenza-like illness (ILI).

Correspondence: P. G. Thomas, PhD, Department of Immunology, St. Jude Children's Research Hospital, MS 351, 262 Danny Thomas Place, Memphis, TN 38105 (Paul.Thomas@stjude.org).

^aPresent affiliation: Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, D. C.

^bR. J. W. and P. G. T. are joint final authors.

^cMembers of the study group are listed at the end of the text.

Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

STUDY GROUP MEMBERS

Members of the study group were as follows: Nikki Turner, Michael Baker, Cameron Grant, Colin McArthur, Sally Roberts, Adrian Trenholmes, Conroy Wong, Susan Taylor, Mark Thompson, Diane Gross, and Jazmin Duque (SHIVERS Science Management Team); Kathryn Haven, Debbie Aley, Pamela Muponisi, Bhamita Chand, Yan Chen, Laurel Plewes, and Frann Sawtell (the research nurses at Auckland District Health Board [ADHB]); Shirley Lawrence, Reniza Cogcoy, Jo Smith, Franie Gravidez, Mandy Ma, Shona Chamberlin, Kirstin Davey, Tania Knowles, and Jo-Ann McLeish (the research nurses at Counties Manukau District Health Board [CMDHB]); A. Todd, J. Bocacao, W. Gunn, P. Kawakami, S. Walker, Robyn Madge, and N. Moore (the World Health Organization National Influenza Centre, Institute of Environmental Science and Research); Fahimeh Rahnama (the ADHB Laboratory); and Helen Qiao, Fifi Tse, Mahtab Zibaei, Tirzah Korrapadu, Louise Optland, and Cecilia Dela Cruz (the CMDHB Laboratory).

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Methods.—Peripheral blood lymphocytes were collected from 27 patients with ILI and 27 with SARI, at time of enrollment and then 2 weeks later. Innate and adaptive cellular immune responses were assessed by flow cytometry, and serum cytokine levels were assessed by a bead-based assay.

Results.—During the acute phase, SARI was associated with significantly reduced numbers of circulating myeloid dendritic cells, CD192⁺ monocytes, and influenza virus-specific CD8⁺ and CD4⁺ T cells as compared to ILI. By the convalescent phase, however, most SARI cases displayed continued immune activation characterized by increased numbers of CD16⁺ monocytes and proliferating, and influenza virus-specific, CD8⁺ T cells as compared to ILI cases. SARI was also associated with reduced amounts of cytokines that regulate T-cell responses (ie, interleukin 4, interleukin 13, interleukin 12, interleukin 10, and tumor necrosis factor β) and hematopoiesis (interleukin 3 and granulocyte-macrophage colony-stimulating factor) but increased amounts of a proinflammatory cytokine (tumor necrosis factor α), chemotactic cytokines (MDC, MCP-1, GRO, and fractalkine), and growth-promoting cytokines (PDGFBB/AA, VEGF, and EGF) as compared to ILI.

Conclusions.—Severe influenza cases showed a delay in the peripheral immune activation that likely led prolonged inflammation, compared with mild influenza cases.

Keywords

Influenza; cellular immunity; infection; disease severity; cytokine

While mild influenza can be subclinical or manifest as fever with unremarkable respiratory symptoms, severe influenza is characterized by respiratory complications such as pneumonia, respiratory distress, and even death. Although risk factors such as extremes of age, preexisting health conditions [1], and genetics [2] have been identified through large-scale epidemiological studies, a cohesive understanding of the underlying immunological process, particularly within cellular immunity, is still not well-defined.

Viral clearance, facilitated by neutralizing antibodies and CD8⁺ T cells [3], is an important factor for mitigating severe influenza. While neutralizing antibodies can be induced by past exposure to a similar strain, the induction and regulation of an effective CD8⁺ T-cell response are less well understood. Some studies that have compared the immune response in mild and severe influenza have identified a role for CD8⁺ T cells in mitigating severe influenza [4–6], but this finding has not been unanimous [7, 8]. Further, much less is known about the role of cellular innate immunity, particularly within the monocyte subpopulations. For example, higher proportions of CD14^{lo}CD16⁺ monocytes in the nasal airways were negatively associated with cytokines that predicted severe disease [9], while decreased functionality were reported in conventional monocytes isolated from patients with severe avian influenza virus infections [10]. How and if these changes affect downstream T-cell responses is unknown. Here, our objective is to identify immune signatures associated with severe influenza, with a particular focus on the role of monocytes and adaptive T-cell responses.

The Southern Hemisphere Influenza Vaccine Efficacy Research and Surveillance (SHIVERS) study, based in New Zealand [11], conducts epidemiologic and laboratory

surveillance for respiratory pathogens among patients with mild or severe acute respiratory illness. As part of this study, we profiled the immune status of those with confirmed influenza during the acute and convalescent phases of disease, through a combination of serological assays and multiparameter flow cytometry.

METHODS

Study Design

Participants were enrolled upon commencement of this sub-study, between August and October of 2013, which coincided with the peak influenza season in New Zealand. For mild influenza, participants were recruited from 16 sentinel general practices situated within Auckland. General practitioners and nurses assessed all consultation-seeking patients. If a patient met the World Health Organization case definition for influenza-like illness (ILI) (ie, “an acute respiratory illness [ARI] with a history of fever or measured fever of $\geq 38^{\circ}\text{C}$, and cough, and onset within the past 10 days, and requiring consultation in that general practice” [12] page 14), a respiratory specimen (nasopharyngeal swab or throat swab) was collected. For severe influenza, patients were recruited from 4 publicly funded hospitals in Auckland. Research nurses reviewed daily records of all overnight admitted inpatients with suspected ARI and interviewed them. If a patient met the World Health Organization case definition for severe ARI (SARI) (ie, “an acute respiratory illness with a history of fever or measured fever of $\geq 38^{\circ}\text{C}$, and cough, and onset within the past 10 days, and requiring inpatient hospitalization” [12] page 14), a respiratory specimen was collected. A total of 29 ILI and 39 SARI cases, which included 8 infants, were initially enrolled. We excluded the infants with SARI, to match the age groups of the ILI cases. Two patients with ILI and 4 with SARI had to be excluded because they were not registered in the central study database. A total of 27 ILI and 27 SARI cases were included for this study.

The respiratory samples were tested for influenza viral RNA by real-time reverse-transcription polymerase chain reaction analysis at the Institute for Environmental Science and Research. Patients whose respiratory sample tested positive for influenza virus were then contacted by the study nurse to undergo collection of the first whole-blood and sera specimens (ie, the acute-phase specimens). A second blood sample was collected 2 weeks later (ie, the convalescent-phase sample). Samples were processed at a central laboratory to isolate the peripheral blood mononuclear cells (PBMCs), using Ficoll-Paque (GE Lifesciences). Cells were stored in liquid nitrogen, while sera were stored at -80°C until use. Serological testing for antibody titers was done using the vaccine strains for the 2013 southern hemisphere influenza season or the relevant strain in circulation. Study data were collected and managed using Research Electronic Data Capture tools hosted at the Institute for Environmental Science and Research [13]. Additional details are provided in the Supplementary Materials.

Flow Cytometry

Antibody clones used in this study are listed in Supplementary Table 1. Intracellular cytokine (ICS) staining was performed on cells stimulated *in vitro*, using pooled peptides (BEI Resources) derived from the influenza virus matrix protein (M), nucleoprotein (NP),

and polymerase basic 1 protein (PB1). Phytohemagglutinin or medium alone were used as controls. Samples were acquired on an LSRII flow cytometer (Becton Dickinson) and analyzed using FlowJo, version 10 (FlowJo). For some assays, not all samples were analyzed, owing to sample availability (eg, poor PBMC viability). Data are expressed as absolute cell numbers or as percentages of the parent population. Medians are used to describe the average responses, and interquartile ranges (IQR) are used to describe the variability. The lower and upper limits of IQR is determined by $Q1 - 1.5(IQR)$ and $Q3 + 1.5(IQR)$, respectively.

Detection of Cytokines

The Luminex MAP system was used with a Milliplex MAP 41-plex human cytokine immunoassay (Millipore) performed according to the manufacturer's protocol.

Statistical Analysis

Descriptive statistical analyses were performed for demographic and clinical data. Continuous variable data were log transformed (if the assumption of normality was not met), and differences between the ILI and SARI groups were analyzed by the Student *t* test, using GraphPad Prism (version 5.03). Probability values of $<.05$ are considered statistically significant and denoted by an asterisk. Cytokine data were analyzed using ordinal logistic regression in Stata 14, after adjustment for age, ethnicity, and time of sampling. Given the large number of cytokines examined, Bonferroni correction was applied for a more stringent test for significance. Univariate or multivariate associations with *P* values of $.001$ were considered statistically significant. Data can be made available upon request.

Ethics Statement

This study received ethics approval from the New Zealand Northern (A) Health and Disability Ethics Committee under references NTX/11/11/102/AM02, AM05, AM06, and AM14. All participants provided written consent to participate in the study.

RESULTS

Study Population

A total of 27 ILI cases and 27 SARI cases were included in the study (Table 1) and were similar in terms of age, sex, and ethnicity. The time from self-reported symptoms to collection of the first blood specimen was slightly longer for the ILI group (mean [\pm SD], 13.7 ± 4.6 days) as compared to the SARI group (10.7 ± 4.8 days), although this difference was not statistically significant. A majority of the cases (72% in the ILI group and 83% in the SARI group) were A/H3 positive, while the remaining cases were influenza B virus positive. Seventy-six percent of individuals with SARI reported relevant underlying conditions, the most common being asthma and chronic lung diseases, while no underlying conditions were reported in the ILI group.

Most SARI cases were relatively mild (median hospitalization duration, 2 days). Sixty-six percent received a diagnosis of uncomplicated febrile illness with respiratory symptoms. Of those who were hospitalized for >3 days, 75% (6 of 8) received a severe diagnosis, owing to

exacerbation of an underlying respiratory condition or pneumonia. One patient was admitted to the intensive care unit, with a stay of 5 days. Two others received oxygen therapy. Although antibiotics were prescribed in 92% of SARI cases, we recovered detailed data on antibiotic use only for 10 cases. Only 2 patients received the immunomodulatory macrolide-class antibiotic roxithromycin. Oseltamivir was prescribed in only 12.5% of SARI cases.

We found no significant differences in antibody levels (targeting either hemagglutinin or neuraminidase) or polymerase chain reaction cycle threshold values between ILI and SARI (Supplementary Figure 1), suggesting that acute-stage antibody titers and early viral load, as detected in the upper respiratory tract swab specimens, were not strong correlates of disease severity in our cohort.

SARI Cases Have Myeloid Dendritic Cells (mDCs) and CD16+ Monocytes Increase in SARI Cases Between the Acute and Convalescent Phases of Disease

Both innate and adaptive immune cells present in the PBMCs collected during the acute and convalescent phases were evaluated. In the innate arm, the frequency and number of mDCs (HLA-DR⁺CD14⁻CD11c⁺) were significantly lower during acute SARI as compared to ILI ($P < .01$; Figure 1A and 1B). By the convalescent phase, the mDC population in the SARI group had increased more significantly, compared with that in the ILI group (frequency change, 5.3% vs 4.4%; $P < .05$; Figure 1C and 1D), resulting in comparable levels between the 2 groups.

In the 3 monocytes subpopulations that we evaluated (ie, the classical [CD14⁺⁺/CD16⁻], inflammatory [CD14⁺⁺/CD16⁺], and patrolling [CD14^{lo}/CD16⁺] subpopulations) [9, 15, 16], differences between ILI and SARI were observed during the convalescent phase (Figure 2A). Expansion of classical (CD16⁻) monocytes to CD16⁺ monocytes is a hallmark of inflammation, and there were significantly more CD16⁺ monocytes during the convalescent phase in the SARI group as compared to the ILI group ($P < .05$). This is due to the increase in both inflammatory monocytes {from 7.9% (IQR [upper, lower limits], 18% [-24.4, 47.6]) to 17.7% (IQR, 17% [-19.7, 48.5])} and patrolling monocytes {from 13% (IQR, 17% [-19.8, 47.1]) to 15.9% (IQR, 13% [-11.4, 41.7])} in patients with SARI. The patrolling monocytes, which are considered to have more-potent antiviral activity [16, 17], were significantly higher in the SARI group, compared with the ILI group, during the convalescent phase ($P < .05$). In the ILI group, the median frequencies remained fairly constant between the 2 time points.

CD192 Expression on Monocyte Populations Is Lower in SARI Cases During the Acute Phase, Suggesting a Reduced Mobilization Process

Aside from assessing the frequencies, we also assessed the monocytes' chemotactic potential by enumerating the proportion that expressed CD192 (otherwise known as "CCR2"). This chemokine receptor is important to mobilize monocytes from the bone marrow to the site of inflammation [18]. The frequencies of CD192⁺ monocytes were, on average, lower in the SARI group than in the ILI group {65% (IQR, 19% [29.8, 109]) vs 75% (IQR, 17% [38.9, 108]); $P = .05$ } during the acute phase (Figure 2B), particularly on the patrolling monocytes {25% (IQR, 13% [-2.5, 51.1]) vs 41% (IQR, 31% [-30.4, 93.7]); Figure 2C}. By the

convalescent phase, however, the frequency of CD192⁺ monocytes underwent a greater increase in the SARI group than in the ILI group for both CD16⁺ subpopulations (inflammatory, 19%; patrolling, 13%; Figure 2D), resulting in comparable levels between the 2 groups.

Thus, between the acute and convalescent phase, levels of mDCs, CD16⁺ monocytes, and CD192⁺ monocytes increased significantly in the SARI group but remained relatively stable in the ILI group, suggesting that the innate immune response in the latter group could be returning (or returned) to basal levels, while dynamic changes are still occurring in the SARI group.

SARI Cases Involved Prolonged Activation of T-Cell Responses

For the adaptive immune response, we assessed the numbers of total and influenza virus-specific CD8⁺ and CD4⁺ T cells. The proportions of total CD8⁺ (Figure 3A) and CD4⁺ (Figure 3B) T cells during the acute phase were comparable between the groups. The frequencies of these cells declined in the ILI group {from 6.0% (IQR, 4.2% [-2, 14.8]) to 4.9% (IQR, 3.7% [-2.3, 12.4]) among CD8⁺ T cells and from 12.0% (IQR, 11.3% [-11.9, 33.2]) to 8.3% (IQR, 6.3% [-4.3, 21.1]) among CD4⁺ T cells}, whereas they increased in the SARI group {from 5.3% (IQR, 6.8% [-6.9, 20.3]) to 8.3% (IQR, 5.0% [-1.6, 18.3]) and from 9.0% (IQR, 9.9% [-10.5, 29.1]) to 11.4% (IQR, 6.7% [-2.2, 24.6]), respectively} by the convalescent phase.

In the in vitro stimulation assay to assess influenza virus-specific T-cell responses, there were relatively high numbers of interferon γ (IFN- γ)-expressing cells in the unstimulated samples (considered the baseline response), potentially due to the recent infection. Thus, in the interest of transparency, we analyzed our peptide-stimulated response both without and with subtraction of baseline values. Although the latter represents data from only a fraction of individuals within each group, it nonetheless represents a bona fide influenza virus-specific response.

Without baseline subtraction, although there was no statistically significant difference, acute SARI cases tended to have fewer influenza virus-specific IFN- γ -expressing CD8⁺ T cells than acute ILI cases under all stimulation conditions (Figure 3C). By the convalescent phase, these numbers and percentage had increased for the SARI group but declined for the ILI group. Similarly, there were also significantly fewer IFN- γ -expressing CD4⁺ T cells during acute SARI as compared to acute ILI, but by the convalescent phase these numbers had increased to comparable levels between the 2 (Figure 3D). After subtracting the baseline response, the SARI group had fewer IFN- γ -expressing CD8⁺ T cells than the ILI group only during the acute phase ($P < .05$; Figure 3E). No significant differences in the IFN- γ -expressing CD4⁺ T-cell response between ILI and SARI cases were detected at any time point (Figure 3F). Collectively, these data demonstrate that there is a reduced influenza virus-specific IFN- γ ⁺ T-cell response during SARI, particularly for the CD8⁺ T-cell compartment, compared with ILI, during the acute phase.

No significant difference between the ILI and SARI groups were observed for T cells expressing tumor necrosis factor α (TNF- α) or both IFN- γ and TNF- α (data not shown).

We also assessed the proliferation (Ki67⁺Bcl-2⁻) and activation (HLA-DR⁺CD38⁺) status [19, 20] of these T cells (Figure 4A). The differences in these T-cell populations between the ILI and SARI groups were again more marked during the convalescent phase. Patients with SARI had higher frequencies of proliferating CD8⁺ T cells {1.3% (IQR, 0.8% [-0.4, 2.9]) specific for M1 epitopes, 1.2% (IQR, 0.7% [-0.1, 2.5]) specific for NP epitopes, and 1.2% (IQR, 0.7% [-0.3, 2.7]) specific for PB1 epitopes} than patients with ILI {1.0% (IQR, 0.8% [-0.72, 2.5]), 0.8% (IQR, 0.6% [-0.2, 2.1]), and 0.8% (IQR, 0.7% [-0.62, 2.3]), respectively; $P < .05$; Figure 4B}. The SARI group also had greater percentages of activated CD38⁺CD8⁺ T cells, particularly those specific for NP and PB1 epitopes {4.2% (IQR, 3.3% [-3.2, 10.2]) and 3.1% (IQR, 1.6% [-0.15, 6.3]), respectively}, than the ILI group {2.6% (IQR, 2.7% [-2.9, 7.8]) and 2.3% (IQR, 2.2% [-2.4, 6.4]), respectively; $P < .05$; Figure 4C}. These differences were not observed in the CD4⁺ T-cell population. We also found no significant correlation between the CD4⁺ T-cell responses and the convalescent-phase antibody titers (data not shown), despite evidence suggesting otherwise [5, 21]. Of note, there were also no statistically significant differences in the convalescent HAI, NAI, and influenza virus-specific IgG antibody titers between the ILI and SARI groups (data not shown).

Differences in Cellular Immunity Are Reflected in Cytokine Profiles

To determine whether the cellular immune responses were reflected in cytokine profiles, we analyzed the levels of 41 cytokines in patients' sera. By adjusting for age, ethnicity and sampling time, we were able to identify key cytokines that were negatively or positively associated with SARI (Table 2). Descriptive statistics for the cytokine concentrations are shown in Supplementary Table 2 and Supplementary Figure 2.

Most of the 8 cytokines that were negatively associated with SARI were involved in priming and regulating T-cell responses. Interleukin 4 (IL-4) and interleukin 13 (IL-13) are important regulators of the T-helper type 2 (Th2) response, while interleukin 12p40 (IL-12p40) and IL-12p70 (as part of the IL-12 complex) are important for priming Th1 responses. The proinflammatory cytokines, TNF- β and IFN- α 2 and the growth factors, interleukin 3 and granulocyte-macrophage colony-stimulating factor were also negatively associated with SARI cases. Conversely, cytokines that were positively associated with SARI cases were growth factors and proinflammatory, chemotactic cytokines that regulate innate immunity. Cytokines such as VEGF, EGF, PDGFBB, and PDFGAA are important in tissue regeneration and wound repair, while granulocyte colony-stimulating factor stimulates the proliferation of leukocytes, particularly neutrophils. MCP1, fractalkine, interleukin 8 (IL-8), and GRO are chemo-attractants for monocytes, neutrophils, natural killer cells, and T cells. Other cytokines that were associated with SARI cases were the proinflammatory cytokine TNF- α and the Th2-promoting (but not cell-derived) cytokines interleukin 5 (IL-5) and soluble CD40L. Collectively, the cytokine profile in SARI individuals suggested an overall condition that was suboptimal for the induction of adaptive T-cell responses but enriched in cytokines that promote cellular infiltration of innate cells and tissue repair.

DISCUSSION

Differences in study design and definitions of study groups have proved to be a major challenge in identifying a clear immune signature for severe influenza [4, 5, 7, 9]. Here, by comparing the response in ILI and SARI cases, we found a discernible immunophenotype, suggesting a difference in response kinetics that does not seem to be strain-dependent.

The cytokine profile in SARI cases suggested a potential link between the innate immune response within the macrophage and DC populations and downstream T-cell responses. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are potent hematopoietic stimulators secreted by macrophages and epithelial cells and, in the presence of IL-4, promote the maturation of dendritic cells [22]. Suboptimal levels of these cytokines could explain the lower numbers of mature DCs in SARI. Since activated DCs and macrophages are in turn the major sources of IL-12, a potent activator of the downstream Th1 response [23], this could lead to the reduced CD8⁺ T-cell responses seen in SARI. Lower serum IL-12 levels have been observed in severely ill patients with influenza or respiratory syncytial virus infection, compared with patients with mild cases [10, 22, 24–26], confirming that IL-12 is important in modulating the outcome of respiratory infections. The SARI cytokine profile also revealed a strong association with chemotactic cytokines regulating the innate immune cells. However, this enhanced chemotactic potential may not be beneficial, as extensive immune cell infiltration could lead to excessive tissue damage. GRO and IL-8, which are potent neutrophil chemo-attractants, are the key mediators of acute lung injury during inflammation [27] and have been associated with acute respiratory distress syndrome [27, 28]. The positive association of platelet factors that are an integral part to the wound healing process [29] also suggests that individuals with severe influenza may have experienced more tissue damage than individuals with mild influenza.

Unexpectedly, the canonical Th2 cytokines IL-4 and IL-13 were negatively associated with SARI, although another Th2 cytokine, IL-5, was not. IL-4 and IL-13 signal through a shared receptor, IL-4R α , but not IL-5, suggesting that different Th2-responses might underlie severe and mild disease processes. It is possible that stimulation of Th2 responses through IL-4 and IL-13 contributed to the rapid tissue repair, as has been proposed recently [30, 31], in mild influenza. In contrast, IL-5 and some IL-13 cytokines are produced mainly by innate lymphoid type 2 cells and invariant natural killer T cells and are key mediators during allergic airway inflammation [32, 33]. Given that asthma and chronic lung diseases were the most commonly reported underlying condition for our SARI cases, it is possible that the positive association of IL-5 with SARI reflected the exacerbation of underlying conditions in these patients.

Numerous studies have studied the cytokine responses of patients with influenza in the attempt to identify markers of disease progression or severity. Our finding that severe influenza is associated with cytokines that regulate the innate immune cells, particularly IL-8, MCP-1, and TNF- α , are in agreement with findings by Lee et al [34] and Davey et al [35], whose studies involved patients infected with 2009 pandemic influenza A(H1N1) virus. However, in contrast to these and other studies [26, 36], our model did not find any statistically significant association between interleukin 6 and interleukin 10 and disease

severity. This is likely related to the relatively late collection of the acute-phase sample, since serum levels of interleukin 6 could return to baseline within a week after symptom onset [36]. In addition, direct comparison between our findings and those of these studies is complicated by the differences in study designs and virus strains.

There are 2 possible interpretations of the findings in our study. The first is that severe influenza is caused by a delayed activation of critical immune cells, as was shown for human cases of avian influenza A(H7N9) virus [5] and 2009 pandemic influenza A(H1N1) virus [4] infection. These studies showed that severity was associated with a delayed induction of natural killer cells and influenza virus-specific CD8⁺ T-cell responses [5]. However, the lower numbers of peripheral immune cells during the acute phase in severe influenza could also be a consequence of aggressive trafficking into the airways and not a truly deficient immune response. Certainly, the few studies that compared peripheral versus site-of-infection profiles have reported much more robust local immune responses in the airways and lungs [7, 9] as compared to the peripheral blood [37]. Nonetheless, regardless of either scenario, the higher numbers of activated immune cells in the circulation during the convalescent phase suggests that individuals with severe influenza continue to experience a prolonged state of immune activation.

There are several limitations in the present study. First, the majority of the SARI cases were relatively mild, with very few cases requiring intensive care unit admission. Thus, our data does not truly capture the immune profile of those on the far end of the severity spectrum. In addition, there could also be an enrollment overlap between the patients with ILI and the briefly hospitalized patients with SARI, owing to health-seeking behavior. This could explain the low statistical support for some of our data. Second, a majority of the SARI cases have underlying conditions. As alluded to previously, it is possible that the immune response profile differs in those with specific underlying conditions. This study is not powered to examine this or other potentially confounding factors and thus could only generalize the immune features underlying mild and severe influenza. Third, owing to logistical challenges, our first sampling time point was relatively late after symptom onset, limiting our ability to capture early events after infection. Nevertheless, our data shows that, cases of mild and severe influenza exhibit differing kinetics of peripheral immune response, consequently resulting in prolonged immune activation in the severe influenza cases.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments.

We thank Cherise M. Guess (St. Jude Children's Research Hospital), for manuscript editing services, and the University of Auckland, for the use of their flow cytometry core facilities. Q. S. H. was the lead investigator for the overall SHIVERS study. P. T. and R. J. W. conceived and designed the immunological experiments. S.-S. W., C. M. O., X.-Z. J. G., and J. R. performed the laboratory assays and the analysis of the serology and cellular data. B. W., C. N., and T. W. were responsible for data management and statistical analyses. M.-A. W. oversaw the overall SHIVERS program and provided critical input for the manuscript. R. S. was the project coordinator. G. R. led the patient enrollment and sample collection process. S.-S. W., R. J. W., and P. G. T. wrote the manuscript.

Financial support. This work was supported by the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (cooperative agreement 1U01IP000480-01 between the Institute for Environmental Science and Research and the CDC's National Center for Immunization and Respiratory Diseases Influenza Division).

References

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. *JAMA* 2004; 292:1333–40. [PubMed: 15367555]
2. Valkenburg SA, Josephs TM, Clemens EB, et al. Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses. *Proc Natl Acad Sci U S A* 2016; 113:4440–5. [PubMed: 27036003]
3. Chiu C, Openshaw PJ. Antiviral B cell and T cell immunity in the lungs. *Nat Immunol* 2015; 16:18–26. [PubMed: 25521681]
4. Fox A, Le NM, Horby P, et al. Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. *PLoS One* 2012; 7:e31535.
5. Wilk E, Pandey AK, Leist SR, et al. RNAseq expression analysis of resistant and susceptible mice after influenza A virus infection identifies novel genes associated with virus replication and important for host resistance to infection. *BMC Genomics* 2015; 16:655. [PubMed: 26329040]
6. Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. *Nat Med* 2013; 19:1305–12. [PubMed: 24056771]
7. Zhao Y, Zhang YH, Denney L, et al. High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection. *Am J Respir Crit Care Med* 2012; 186:1292–7. [PubMed: 23087026]
8. Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. *Nat Med* 2012; 18:274–80. [PubMed: 22286307]
9. Oshansky CM, Gartland AJ, Wong SS, et al. Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load. *Am J Respir Crit Care Med* 2014; 189:449–62. [PubMed: 24308446]
10. Diao H, Cui G, Wei Y, et al. Severe H7N9 infection is associated with decreased antigen-presenting capacity of CD14+ cells. *PLoS One* 2014; 9:e92823.
11. Huang QS, Turner N, Baker MG, et al. Southern hemisphere influenza and vaccine effectiveness research and surveillance. *Influenza Other Respir Viruses* 2015; 9:179–90. [PubMed: 25912617]
12. World Health Organization. Global epidemiological surveillance standards for influenza (Page 14). http://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influenza_Surveillance_Standards_2014.pdf Accessed 9 December 2017.
13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009; 42:377–81. [PubMed: 18929686]
14. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. *J Infect Dis* 2009; 200:492–500. [PubMed: 19591575]
15. Abeles RD, McPhail MJ, Sowter D, et al. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi)/CD16(neg) monocytes: Expansion of CD14(hi)/CD16(pos) and contraction of CD14(lo)/CD16(pos) monocytes in acute liver failure. *Cytometry A* 2012; 81:823–34. [PubMed: 22837127]
16. Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity* 2010; 33:375–86. [PubMed: 20832340]
17. Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. *Immunol Res* 2012; 53:41–57. [PubMed: 22430559]
18. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. *Nat Immunol* 2006; 7:311–7. [PubMed: 16462739]

19. McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. *Proc Natl Acad Sci U S A* 2015; 112:4719–24. [PubMed: 25775592]
20. Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. *Immunity* 2008; 28:710–22. [PubMed: 18468462]
21. Nayak JL, Fitzgerald TF, Richards KA, Yang H, Treanor JJ, Sant AJ. CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine. *J Infect Dis* 2013; 207:297–305. [PubMed: 23148285]
22. Martinez-Moczygamba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. *J Allergy Clin Immunol* 2003; 112:653–665; quiz 66. [PubMed: 14564341]
23. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. *Nat Rev Immunol* 2011; 11:762–74. [PubMed: 21984070]
24. Pinto RA, Arredondo SM, Bono MR, Gaggero AA, Díaz PV. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol. *Pediatrics* 2006; 117:e878–86. [PubMed: 16618789]
25. Heltzer ML, Coffin SE, Maurer K, et al. Immune dysregulation in severe influenza. *J Leukoc Biol* 2009; 85:1036–43. [PubMed: 19276177]
26. Yu X, Zhang X, Zhao B, et al. Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6. *PLoS One* 2011; 6:e28680.
27. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? *Am J Physiol Lung Cell Mol Physiol* 2014; 306:L217–30. [PubMed: 24318116]
28. Villard J, Dayer-Pastore F, Hamacher J, Aubert JD, Schlegel-Haueter S, Nicod LP. GRO alpha and interleukin-8 in *Pneumocystis carinii* or bacterial pneumonia and adult respiratory distress syndrome. *Am J Respir Crit Care Med* 1995; 152:1549–54. [PubMed: 7582292]
29. Martínez CE, Smith PC, Palma Alvarado VA. The influence of platelet-derived products on angiogenesis and tissue repair: a concise update. *Front Physiol* 2015; 6:290. [PubMed: 26539125]
30. Chen F, Liu Z, Wu W, et al. An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. *Nat Med* 2012; 18:260–6. [PubMed: 22245779]
31. Pulendran B, Artis D. New paradigms in type 2 immunity. *Science* 2012; 337:431–5. [PubMed: 22837519]
32. Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. *Cytokine* 2015; 75:25–37. [PubMed: 26073683]
33. Zhu J T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. *Cytokine* 2015; 75:14–24. [PubMed: 26044597]
34. Lee N, Wong CK, Chan PK, et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. *PLoS One* 2011; 6:e26050.
35. Davey RT Jr, Lynfield R, Dwyer DE, et al.; INSIGHT FLU 002 and 003 Study Groups. The association between serum biomarkers and disease outcome in influenza A(H1N1) pdm09 virus infection: results of two international observational cohort studies. *PLoS One* 2013; 8:e57121.
36. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. *J Clin Invest* 1998; 101:643–9. [PubMed: 9449698]
37. Wang Z, Zhang A, Wan Y, et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. *Proc Natl Acad Sci U S A* 2014; 111:769–74. [PubMed: 24367104]




Figure 1. Differences in the myeloid dendritic cell (mDC) ($CD14^-CD11^+$) population in ILI (black) and severe acute respiratory illness (SARI; red) influenza cases during the acute and convalescent phase. Percentages and absolute cell counts of mDCs in patients with ILI and SARI during the acute (A and B) and convalescent (C and D) phases of disease. * $P < .05$.





Figure 2. Differences in the monocyte subpopulations in influenza-like illness (ILI; black) and severe acute respiratory illness (SARI; red) influenza cases during the acute and convalescent phases of disease. Monocyte populations are identified on the basis of the relative expression level of the markers CD14 and CD16 as CD14⁺⁺/CD16⁻ (classical), CD14⁺⁺/CD16⁺ (inflammatory), and CD14^{lo}/CD16⁺ (patrolling) monocytes. *A*, Percentages of each monocyte subpopulation (per the total monocyte population) during the acute and convalescent phases. *B*, Percentages of CD192⁺ cells in the total monocyte population during the acute and convalescent phases. *C*, Percentages of CD192⁺ cells per monocyte

subpopulation in ILI and SARI during the acute and convalescent phases. Lines represent medians, and error bars represent interquartile ranges. *D*, Change in percentages of CD192⁺ monocytes in each subpopulation between acute and convalescent samples. Values were obtained by subtracting acute values from the convalescent value. **P* < .05; NS, not statistically significant.






Figure 3. Differences in the adaptive immunity in influenza-like illness (ILI; black) and severe acute respiratory illness (SARI; red) influenza cases. *A* and *B*, Percentages and absolute cell counts of CD3⁺CD8⁺ (*A*) and CD3⁺CD4⁺ (*B*) T cells during the acute and convalescent phases. *C* and *D*, Interferon γ (IFN- γ)-expressing CD8⁺ (*C*) and CD4⁺ (*D*) T cells, expressed as percentage of gated lymphocytes, and absolute cell counts detected in each stimulation condition (unstimulated, matrix 1 protein [M1], nucleoprotein [NP], polymerase basic 1 protein [PB1], and phytohemagglutinin [PHA]; without baseline subtracted). *E* and

F, Total influenza virus-specific IFN- γ -expressing CD8⁺ (*E*) and CD4⁺ (*F*) T-cell responses after peptide (M1, NP, and PB1) stimulation (with the baseline value subtracted). Data are expressed as medians, and error bars represent interquartile ranges. **P* < .05, ***P* < .01.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Differences in the proliferating and activated, effector T cells and in influenza-like illness (ILI; black) and severe acute respiratory illness (SARI; red) influenza cases. *A*, Representative flow plots depicting the gating strategy for identification of Ki67⁺Bcl2⁻ proliferating (top left) and CD38⁺ activated, effector (top right) populations. *B* and *C*, Percentages of proliferating (Ki67⁺Bcl2⁻) CD4⁺ or CD8⁺ T cells (*B*) and percentages of

effector (CD38⁺) CD4⁺ or CD8⁺ T cells (C) during the acute and convalescent phases of disease. Lines represent medians, and error bars represent interquartile ranges. **P* < .05.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

Demographic and Clinical Characteristics of 27 Study Participants With Influenza-Like Illness (ILI) and 27 With Severe Acute Respiratory Illness (SARI)

| Variable | ILI | SARI |
|---|----------------|----------------|
| Interval between sampling, d, mean \pm SD | 15.9 \pm 1.8 | 15.3 \pm 2.4 |
| Interval between symptom onset and initial sampling, d, mean \pm SD | 13.7 \pm 4.6 | 10.7 \pm 4.8 |
| Age, y, median (range) | 40 (12–77) | 45 (12–78) |
| Sex | | |
| Male | 10/27 (37.0) | 10/27 (37.0) |
| Female | 17/27 (63.0) | 17/27 (63.0) |
| Ethnicity | | |
| Aslan | 3/27 (11) | 0/27 (0) |
| Maori | 2/27 (7) | 5/27 (18) |
| Other | 16/27 (59) | 13/27 (48) |
| Pacific | 5/27 (19) | 8/27 (30) |
| Unknown | 1/27 (4) | 0/27 (0) |
| Infecting Influenza virus (sub)type | | |
| A(H3N2) | 18/27 (72) | 24/27 (83) |
| B | 7/27 (28) | 4/27 (14) |
| Coinfected (with IBV/other pathogen) | 0/27 | 1/27 (3.5) |
| Hospitalization duration, d, median (range) | 0 | 2 (1–10) |
| Reported relevant underlying conditions, no. | 0 | 19/25 (76) |
| Received vaccination in past year | ND | 15/26 (60) |
| Clinical diagnosis | | |
| Febrile illness with respiratory symptoms | | 8/25 (66) |
| Suspected pneumonia | ... | 6/25 (25) |
| Exacerbation of adult chronic lung disease | ... | 3/25 (12) |
| Exacerbation of asthma | ... | 2/25 (8) |
| Exacerbation of childhood chronic lung disease | ... | 2/25 (8) |
| Other suspected acute respiratory infection | ... | 2/25 (8) |
| Respiratory failure | ... | 1/25 (4) |
| Suspected acute URTI | ... | 1/25 (4) |
| Clinical care | | |
| Received oseltamivir | ... | 3/24 (12.5) |
| Received antibiotics | ... | 23/25 (92) |
| Received statin | ... | 4/24 (16) |
| ICU stay | ... | 1/27 |
| Received assisted ventilation | ... | 2/27 |

Data are proportion (%) of patients, unless otherwise indicated.

Abbreviations: IBV, influenza B virus; ICU, intensive care unit; ND, no data; URTI, upper respiratory tract infection.

Table 2.

Cytokines That Were Negatively or Positively Associated With Severe Acute Respiratory Illness (SARI)

| Association, Cytokine | Regression Coefficient | | P | |
|-----------------------|------------------------|-----------------------|------------|-----------------------|
| | Univariate | Adjusted ^a | Univariate | Adjusted ^a |
| Negative | | | | |
| IL-3 | -3.3 | -3.29 | <.001 | .001 |
| IL-12p40 | -2.55 | -2.44 | <.001 | <.001 |
| IL-12p70 | -2.37 | -2.09 | <.001 | .002 |
| TNF-β | -1.85 | -2.03 | .003 | .001 |
| IL-13 | -2.01 | -1.81 | <.001 | <.001 |
| IL-4 | -1.53 | -1.46 | <.001 | .004 |
| GM-CSF | -1.67 | -1.32 | <.001 | .003 |
| IFN-α2 | -1.32 | -1.26 | .001 | .008 |
| Positive | | | | |
| sCD40L | 1.52 | 1.54 | <.001 | .001 |
| EGF | 1.66 | 1.72 | <.001 | .002 |
| G-CSF | 2.32 | 1.87 | .001 | .015 |
| PDGFBB | 1.76 | 1.9 | <.001 | .001 |
| TNF-α | 2.47 | 2 | <.001 | <.001 |
| MCP-1 | 2.47 | 2.14 | <.001 | <.001 |
| IL-8 | 2.67 | 2.25 | <.001 | .001 |
| IL-5 | 3.79 | 3.71 | <.001 | <.001 |
| GRO | 4.18 | 3.83 | <.001 | .002 |
| Fractalkine | 16.88 | 16.52 | <.001 | <.001 |
| VEGF | 17.33 | 17.34 | <.001 | <.001 |
| PDGFAA | 18.22 | 19.24 | <.001 | <.001 |

Abbreviations: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-α2, interferon α2; IL-3, interleukin 3; IL-4, interleukin 4; IL-5, interleukin 5; IL-8, interleukin 8; IL-12, interleukin 12; IL-13, interleukin 13; sCD40L, soluble CD40L; TNF-α, tumor necrosis factor α; TNF-β, tumor necrosis factor β.

^aAdjusted for age, ethnicity, and time to sample collection. Only cytokines with *P* values of .001 in either univariate or adjusted models were listed.